Brief: Larimar Therapeutics Q4 Net Income USD -28.824 Million
Mar 24 (Reuters) - Larimar Therapeutics Q4 operating expenses USD 31.293 million. Q4 basic EPS USD -0.45 Q4 income from operations USD -31.293 million
Recent news on Larimar Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
Larimar tumbles as safety concerns resurface in rare disease drug study update
U.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
U.S. STOCKS ON THE MOVE-SpaceX, Charter, Gulfport Energy
Larimar tumbles as safety concerns resurface in rare disease drug study update